Citations (114)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Aneta Mela, Elżbieta Rdzanek, Andrzej Tysarowski, Magdalena Sakowicz, Janusz Jaroszyński, Marzena Furtak-Niczyporuk, Grzegorz Żurek, Łukasz A. Poniatowski & Beata Jagielska. (2023) The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 23:1, pages 43-54.
Read now
Read now
Denise Battaglini, Chiara Robba, Paolo Pelosi & Patricia R.M. Rocco. (2022) Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs 27:2, pages 187-209.
Read now
Read now
Sidsel Pedersen, Kirstine Ostenfeld Larsen, Alex Hørby Christensen, Inge Marie Svane, Bo Zerahn & Eva Ellebaek. (2022) Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncologica 61:1, pages 45-51.
Read now
Read now
Elnaz Faghfuri, Shekoufeh Nikfar, Kamal Niaz, Mohammad Ali Faramarzi & Mohammad Abdollahi. (2018) Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Expert Opinion on Drug Metabolism & Toxicology 14:3, pages 317-330.
Read now
Read now
Khiem A Tran, Michelle Y Cheng, Anupam Mitra, Hiromi Ogawa, Vivian Y Shi, Laura P Olney, April M Kloxin & Emanual Maverakis. (2016) MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Design, Development and Therapy 10, pages 43-52.
Read now
Read now
Klaus G. Griewank. (2016) Biomarkers in melanoma. Scandinavian Journal of Clinical and Laboratory Investigation 76:sup245, pages S104-S112.
Read now
Read now
Luana Lugini, Cristina Federici, Martina Borghi, Tommaso Azzarito, Maria Lucia Marino, Albino Cesolini, Enrico Pierluigi Spugnini & Stefano Fais. (2016) Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry 31:4, pages 538-545.
Read now
Read now
Nabin Khanal & Apar Kishor Ganti. (2016) Emerging targeted therapies in non-small cell lung cancer. Expert Review of Anticancer Therapy 16:2, pages 177-187.
Read now
Read now
Articles from other publishers (106)
Pradeep Kumar Gupta, Stepan Orlovskiy, Fernando Arias-Mendoza, David S. Nelson, Aria Osborne, Stephen Pickup, Jerry D. Glickson & Kavindra Nath. (2024) Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma. Cancers 16:2, pages 365.
Crossref
Crossref
Penglei Wang, Kyle Laster, Xuechao Jia, Zigang Dong & Kangdong Liu. (2023) Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Molecular Cancer 22:1.
Crossref
Crossref
Md Entaz Bahar, Hyun Joon Kim & Deok Ryong Kim. (2023) Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Changyu Shen, Zhenlin Huang, Xiaoman Chen, Zhihao Wang, Jun Zhou, Zhaokun Wang, Dejun Liu, Chenxia Li, Tianqi Zhao, Yang Zhang, Shiqing Xu, Wenjun Zhou & Wei Peng. (2023) Rapid ultra-sensitive nucleic acid detection using plasmonic fiber-optic spectral combs and gold nanoparticle-tagged targets. Biosensors and Bioelectronics 242, pages 115719.
Crossref
Crossref
Yuanyuan Kang, Zhenyu Ji, He Li & Hensin Tsao. (2023) Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping. Journal of Investigative Dermatology 143:5, pages 842-853.e6.
Crossref
Crossref
Chikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, Eiji Shinozaki, Kentaro Yamazaki, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Satoshi Yuki, Kohei Shitara, Hideaki Bando, Yutaka Suzuki, Kiwamu Akagi, Shogo Nomura, Satoshi Fujii, Masaya Sugiyama, Nao Nishida, Masashi Mizokami, Yasuhiro Koh, Takuya Koshizaka, Hideki Okada, Yukiko Abe, Atsushi Ohtsu, Takayuki Yoshino & Katsuya Tsuchihara. (2023) Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. International Journal of Clinical Oncology 28:5, pages 654-663.
Crossref
Crossref
Ali Talebi, Vincent de Laat, Xander Spotbeen, Jonas Dehairs, Florian Rambow, Aljosja Rogiers, Frank Vanderhoydonc, Lara Rizotto, Mélanie Planque, Ginevra Doglioni, Sahar Motamedi, David Nittner, Tania Roskams, Patrizia Agostinis, Oliver Bechter, Veerle Boecxstaens, Marjan Garmyn, Marie O’Farrell, Alan Wagman, George Kemble, Eleonora Leucci, Sarah-Maria Fendt, Jean-Christophe Marine & Johannes V. Swinnen. (2023) Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Crossref
Irene Vanni, Lorenza Pastorino, Enrica Teresa Tanda, Virginia Andreotti, Bruna Dalmasso, Nicola Solari, Matteo Mascherini, Francesco Cabiddu, Antonio Guadagno, Simona Coco, Eleonora Allavena, William Bruno, Gabriella Pietra, Michela Croce, Rosaria Gangemi, Michele Piana, Gabriele Zoppoli, Lorenzo Ferrando, Francesco Spagnolo, Paola Queirolo & Paola Ghiorzo. (2023) Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. International Journal of Molecular Sciences 24:5, pages 4302.
Crossref
Crossref
Denise Battaglini, Brigitta Fazzini, Pedro Leme Silva, Fernanda Ferreira Cruz, Lorenzo Ball, Chiara Robba, Patricia R. M. Rocco & Paolo Pelosi. (2023) Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies. Journal of Clinical Medicine 12:4, pages 1381.
Crossref
Crossref
Anna Lahn Sørensen, Mariann Guldmann-Christensen, Michael Børgesen, Rasmus Koefoed Petersen, Katharina Flugt, Julie Mejer Holmgaard Duelund, Majbritt Hauge Kyneb, Jan Lorenzen, Emma Pipó-Ollé, Samantha Epistolio, Alice Riva, Giulia Dazio, Elisabetta Merlo, Tine Meyer, Ulf Bech Christensen & Milo Frattini. (2023) Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen® FFPE BRAF qPCR assay. PLOS ONE 18:2, pages e0281558.
Crossref
Crossref
Ewelina Madej, Anna A. Brożyna, Agnieszka Adamczyk, Norbert Wronski, Agnieszka Harazin-Lechowska, Anna Muzyk, Krzysztof Makuch, Michal Markiewicz, Janusz Rys & Agnieszka Wolnicka-Glubisz. (2023) Vemurafenib and Dabrafenib Downregulates RIPK4 Level. Cancers 15:3, pages 918.
Crossref
Crossref
Cang Li, Le Kuai, Rutao Cui & Xiao Miao. (2022) Melanogenesis and the Targeted Therapy of Melanoma. Biomolecules 12:12, pages 1874.
Crossref
Crossref
Alexander Schulz, Jennifer Raetz, Paula C. Karitzky, Lisa Dinter, Julia K. Tietze, Isabell Kolbe, Theresa Käubler, Bertold Renner, Stefan Beissert, Friedegund Meier & Dana Westphal. (2022) Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma. Cancers 14:19, pages 4930.
Crossref
Crossref
Dan Wang, Zhibing Fu, Lihua Gao, Jinrong Zeng, Yaping Xiang, Lu Zhou, Xiaoliang Tong, Xiao-Qi Wang & Jianyun Lu. (2022) Increased IRF9–STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis. Journal of Investigative Dermatology 142:9, pages 2476-2487.e9.
Crossref
Crossref
Longyao Zhang, Linpeng Zheng, Qiao Yang & Jianguo Sun. (2022) The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Bernadette Xin Jie Tune, Maw Shin Sim, Chit Laa Poh, Rhanye Mac Guad, Choy Ker Woon, Iswar Hazarika, Anju Das, Subash C. B. Gopinath, Mariappan Rajan, Mahendran Sekar, Vetriselvan Subramaniyan, Neeraj Kumar Fuloria, Shivkanya Fuloria, Kalaivani Batumalaie & Yuan Seng Wu. (2022) Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors. Journal of Oncology 2022, pages 1-25.
Crossref
Crossref
Arlinda Ljoki, Tanzila Aslam, Tina Friis, Ragnhild G. Ohm & Gunnar Houen. (2022) In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology. International Journal of Molecular Sciences 23:8, pages 4277.
Crossref
Crossref
Lanhong Su, Guiyuan Chen, Zhaoji Liu, Yuanzeng Min & Andrew Z. Wang. 2022. Systemic Drug Delivery Strategies. Systemic Drug Delivery Strategies
529
547
.
Shaobin Huang, Wuguo Deng, Peng Wang, Yue Yan, Chuanbo Xie, Xiaoling Cao, Miao Chen, Changlin Zhang, Dingbo Shi, Yunxian Dong, Pu Cheng, Hailin Xu, Wenkai Zhu, Zhicheng Hu, Bing Tang & Jiayuan Zhu. (2021) Fermitin family member 2 promotes melanoma progression by enhancing the binding of p-α-Pix to Rac1 to activate the MAPK pathway. Oncogene 40:37, pages 5626-5638.
Crossref
Crossref
Anna Stagno, Sabrina Vari, Alessio Annovazzi, Vincenzo Anelli, Michelangelo Russillo, Francesco Cognetti & Virginia Ferraresi. (2021) Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?. Frontiers in Oncology 11.
Crossref
Crossref
Anja Wessely, Theresa Steeb, Carola Berking & Markus Vincent Heppt. (2021) How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. International Journal of Molecular Sciences 22:11, pages 5761.
Crossref
Crossref
Stephanie McKenna & Lucía García-Gutiérrez. (2021) Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?. International Journal of Molecular Sciences 22:10, pages 5115.
Crossref
Crossref
Rebaz Ahmed, Ranganayaki Muralidharan, Akhil Srivastava, Sarah E. Johnston, Yan D. Zhao, Suhendan Ekmekcioglu, Anupama Munshi & Rajagopal Ramesh. (2021) Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells. Cancers 13:2, pages 166.
Crossref
Crossref
Prakrit R. Kumar, Jamie A. Moore, Kristian M. Bowles, Stuart A. Rushworth & Marc D. Moncrieff. (2020) Mitochondrial oxidative phosphorylation in cutaneous melanoma. British Journal of Cancer 124:1, pages 115-123.
Crossref
Crossref
Anna M. Czarnecka, Michał Fiedorowicz & Ewa Bartnik. 2021. New Therapies in Advanced Cutaneous Malignancies. New Therapies in Advanced Cutaneous Malignancies
357
384
.
Bruna Dalmasso, Irene Vanni, William Bruno, Virginia Andreotti, Lorenza Pastorino, Francesco Spagnolo & Paola Ghiorzo. 2021. Current Management of Melanoma. Current Management of Melanoma
39
45
.
Francesco Spagnolo, Andrea Boutros, Enrica Tanda, Federica Cecchi & Paola Queirolo. 2021. Current Management of Melanoma. Current Management of Melanoma
167
174
.
Franco De Cian & Matteo Mascherini. 2021. Current Management of Melanoma. Current Management of Melanoma
147
155
.
Laura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, Jennifer Dworacek, Aniello Federico, Marlene Vierthaler, Daniel Novak, Ihor Arkhypov, Thomas Hielscher, Viktor Umansky, Peter Altevogt & Jochen Utikal. (2020) HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma. Cancers 12:12, pages 3761.
Crossref
Crossref
Irene Vanni, Milena Casula, Lorenza Pastorino, Antonella Manca, Bruna Dalmasso, Virginia Andreotti, Marina Pisano, Maria Colombino, Ulrich Pfeffer, Enrica Teresa Tanda, Carla Rozzo, Panagiotis Paliogiannis, Antonio Cossu, Paola Ghiorzo & Giuseppe Palmieri. (2020) Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). Diagnostic Pathology 15:1.
Crossref
Crossref
Qing-Shan Li, Bang-Nian Shen, Hua-Jian Xu & Ban-Feng Ruan. (2020) Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. Anti-Cancer Agents in Medicinal Chemistry 20:12, pages 1415-1430.
Crossref
Crossref
Irene Vanni, Enrica Teresa Tanda, Bruna Dalmasso, Lorenza Pastorino, Virginia Andreotti, William Bruno, Andrea Boutros, Francesco Spagnolo & Paola Ghiorzo. (2020) Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Enrica Teresa Tanda, Irene Vanni, Andrea Boutros, Virginia Andreotti, William Bruno, Paola Ghiorzo & Francesco Spagnolo. (2020) Current State of Target Treatment in BRAF Mutated Melanoma. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Christiane Adrielly Alves Ferraz, Raimundo Gonçalves de Oliveira Júnior, Ana Paula de Oliveira, Hugo Groult, Laureen Beaugeard, Laurent Picot, Edilson Beserra de Alencar Filho, Jackson Roberto Guedes da Silva Almeida & Xirley Pereira Nunes. (2020) Complexation with β-cyclodextrin enhances apoptosis-mediated cytotoxic effect of harman in chemoresistant BRAF-mutated melanoma cells. European Journal of Pharmaceutical Sciences 150, pages 105353.
Crossref
Crossref
Raimundo Gonçalves de Oliveira-Júnior, Nolwenn Marcoult-Fréville, Grégoire Prunier, Laureen Beaugeard, Edilson Beserra de Alencar Filho, Eduard David Simões Mourão, Sylvie Michel, Lucindo José Quintans-Júnior, Jackson Roberto Guedes da Silva Almeida, Raphaël Grougnet & Laurent Picot. (2020) Polymethoxyflavones from Gardenia oudiepe (Rubiaceae) induce cytoskeleton disruption-mediated apoptosis and sensitize BRAF-mutated melanoma cells to chemotherapy. Chemico-Biological Interactions 325, pages 109109.
Crossref
Crossref
Irene Vanni, Enrica Teresa Tanda, Francesco Spagnolo, Virginia Andreotti, William Bruno & Paola Ghiorzo. (2020) The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Anna M. Czarnecka, Ewa Bartnik, Michał Fiedorowicz & Piotr Rutkowski. (2020) Targeted Therapy in Melanoma and Mechanisms of Resistance. International Journal of Molecular Sciences 21:13, pages 4576.
Crossref
Crossref
Spencer Phillips Hey, Cory V. Gerlach, Garrett Dunlap, Vinay Prasad & Aaron S. Kesselheim. (2020) The evidence landscape in precision medicine. Science Translational Medicine 12:540.
Crossref
Crossref
Raimundo Gonçalves de Oliveira-Júnior, Elodie Nicolau, Antoine Bonnet, Grégoire Prunier, Laureen Beaugeard, Nicolas Joguet, Valérie Thiéry & Laurent Picot. (2020) Carotenoids from Rhodomonas salina Induce Apoptosis and Sensitize A2058 Melanoma Cells to Chemotherapy. Revista Brasileira de Farmacognosia 30:2, pages 155-168.
Crossref
Crossref
Hima Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Long Yuan, Samar Alanazi & Joan T. Garrett. (2020) Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers 12:2, pages 482.
Crossref
Crossref
Matilde Monti, Francesca Consoli, Raffaella Vescovi, Mattia Bugatti & William Vermi. (2020) Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. Cells 9:2, pages 417.
Crossref
Crossref
Xintao Yang, Rui Liang, Chunxi Liu, Jessica Aijia Liu, May Pui Lai Cheung, Xuelai Liu, On Ying Man, Xin-Yuan Guan, Hong Lok Lung & Martin Cheung. (2019) SOX9 is a dose-dependent metastatic fate determinant in melanoma. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Cesar S. Huertas, Olalla Calvo-Lozano, Arnan Mitchell & Laura M. Lechuga. (2019) Advanced Evanescent-Wave Optical Biosensors for the Detection of Nucleic Acids: An Analytic Perspective. Frontiers in Chemistry 7.
Crossref
Crossref
Peter J. Houghton & Raushan T. Kurmasheva. (2019) Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews 71:4, pages 671-697.
Crossref
Crossref
Zaman, Wu & Bivona. (2019) Targeting Oncogenic BRAF: Past, Present, and Future. Cancers 11:8, pages 1197.
Crossref
Crossref
Jan Rožanc, Theodore Sakellaropoulos, Asier Antoranz, Cristiano Guttà, Biswajit Podder, Vesna Vetma, Nicole Rufo, Patrizia Agostinis, Vaia Pliaka, Thomas Sauter, Dagmar Kulms, Markus Rehm & Leonidas G. Alexopoulos. (2018) Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death & Differentiation 26:8, pages 1365-1378.
Crossref
Crossref
Raj Shah, Simar J. Singh, Kevinn Eddy, Fabian V. Filipp & Suzie Chen. (2019) Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma. Cancer Research 79:8, pages 1799-1809.
Crossref
Crossref
Christian Wiraja, David C. Yeo, Daniel Chin Shiuan Lio, Mengjia Zheng & Chenjie Xu. (2018) Functional Imaging with Nucleic‐Acid‐Based Sensors: Technology, Application and Future Healthcare Prospects. ChemBioChem 20:4, pages 437-450.
Crossref
Crossref
Eden Rebecca Padayachee, Henry Ademola Adeola, Jennifer Catherine Van Wyk, Fleury Augustine Nsole Biteghe, Shivan Chetty, Nonhlanhla Patience Khumalo & Stefan Barth. (2019) Applications of SNAP‐tag technology in skin cancer therapy. Health Science Reports 2:2.
Crossref
Crossref
Sarah E. Fenton, Jeffrey A. Sosman & Sunandana Chandra. 2019. Cutaneous Melanoma [Working Title]. Cutaneous Melanoma [Working Title].
Laura Hüser, Sachindra Sachindra, Karol Granados, Aniello Federico, Lionel Larribère, Daniel Novak, Viktor Umansky, Peter Altevogt & Jochen Utikal. (2018) SOX2‐mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. International Journal of Cancer 143:12, pages 3131-3142.
Crossref
Crossref
Torben Redmer. (2018) Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. Molecular Cancer 17:1.
Crossref
Crossref
Nina Zila, Andrea Bileck, Besnik Muqaku, Lukas Janker, Ossia M. Eichhoff, Phil F. Cheng, Reinhard Dummer, Mitchell P. Levesque, Christopher Gerner & Verena Paulitschke. (2018) Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. Clinical Proteomics 15:1.
Crossref
Crossref
Xiao Liu, Jinfeng Wu, Haihong Qin & Jinhua Xu. (2018) The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma. Targeted Oncology 13:4, pages 437-446.
Crossref
Crossref
Hui Chen, Rajyalakshmi Luthra, Mark J. Routbort, Keyur P. Patel, Maria E. Cabanillas, Russell R. Broaddus & Michelle D. Williams. (2018) Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Molecular Cancer Therapeutics 17:7, pages 1575-1584.
Crossref
Crossref
Ali Talebi, Jonas Dehairs, Florian Rambow, Aljosja Rogiers, David Nittner, Rita Derua, Frank Vanderhoydonc, Joao A. G. Duarte, Francesca Bosisio, Kathleen Van den Eynde, Kris Nys, Mónica Vara Pérez, Patrizia Agostinis, Etienne Waelkens, Joost Van den Oord, Sarah-Maria Fendt, Jean-Christophe Marine & Johannes V. Swinnen. (2018) Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nature Communications 9:1.
Crossref
Crossref
Ban‐Feng Ruan, Meng‐Xue Lin, Qin Shao, Tian‐Hong Wang, Qing Zhang, Yu‐Lu Dong, Chao‐Nan Bu, Hua‐Jian Xu, Ben‐Guo Zhou & Qing‐Shan Li. (2018)
Modification, Biological Evaluation and
SAR
Studies of Novel 1
H
‐Pyrazol Derivatives Containing
N
,
N
′‐Disubstituted Urea Moiety as Potential Anti‐melanoma Agents
. Chemistry & Biodiversity 15:6.
Crossref
Crossref
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
65
109
.
Breea Buckley & Bradley Pierce. (2018) Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma. Journal of the American Academy of Physician Assistants 31:5, pages 24-26.
Crossref
Crossref
Sarina Gouravan, Leonardo Meza-Zepeda, Ola Myklebost, Eva Stratford & Else Munthe. (2018) Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. International Journal of Molecular Sciences 19:4, pages 969.
Crossref
Crossref
Dian Huang, Kevin A. Leslie, Daniel Guest, Olga Yeshcheulova, Irena J. Roy, Marco Piva, Gatien Moriceau, Thomas A. Zangle, Roger S. Lo, Michael A. Teitell & Jason Reed. (2018) High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity. Analytical Chemistry 90:5, pages 3299-3306.
Crossref
Crossref
Linli Zhou, Kun Yang, Spencer Dunaway, Zalfa Abdel‐Malek, Thomas Andl, Ana Luisa Kadekaro & Yuhang Zhang. (2017)
Suppression of
MAPK
signaling in
BRAF
‐activated
PTEN
‐deficient melanoma by blocking β‐catenin signaling in cancer‐associated fibroblasts
. Pigment Cell & Melanoma Research 31:2, pages 297-307.
Crossref
Crossref
Anthony W. Tolcher, Wei Peng & Emiliano Calvo. (2018) Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. Molecular Cancer Therapeutics 17:1, pages 3-16.
Crossref
Crossref
Galia Maik-Rachline, Izel Cohen & Rony Seger. 2018. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
89
116
.
Sachindra, Lionel Larribère, Daniel Novak, Huizi Wu, Laura Hüser, Karol Granados, Elias Orouji & Jochen Utikal. (2017) New role of ID3 in melanoma adaptive drug-resistance. Oncotarget 8:66, pages 110166-110175.
Crossref
Crossref
Krista Rubin. (2017) MAPK Pathway–Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma
. Clinical Journal of Oncology Nursing 21:6, pages 699-709.
Crossref
Crossref
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'AmelioJrJr, Pingkuan Zhang, Bijoyesh Mookerjee & Bruce E Johnson. (2017) Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. The Lancet Oncology 18:10, pages 1307-1316.
Crossref
Crossref
Merope Griffin, Daniele Scotto, Debra H. Josephs, Silvia Mele, Silvia Crescioli, Heather J. Bax, Giulia Pellizzari, Matthew D. Wynne, Mano Nakamura, Ricarda M. Hoffmann, Kristina M. Ilieva, Anthony Cheung, James F. Spicer, Sophie Papa, Katie E. Lacy & Sophia N. Karagiannis. (2017) BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget 8:44, pages 78174-78192.
Crossref
Crossref
Leslie Calapre, Lydia Warburton, Michael Millward, Mel Ziman & Elin S. Gray. (2017) Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters 404, pages 62-69.
Crossref
Crossref
Kayleigh C. Ross, Andrew J. Andrews, Christopher D. Marion, Timothy J. Yen & Vikram Bhattacharjee. (2017) Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics 16:8, pages 1596-1609.
Crossref
Crossref
Joanna Mangana, Phil F. Cheng, Corina Kaufmann, Valerie C. Amann, Anna L. Frauchiger, Viola Stögner, Ulrike Held, Roger von Moos, Olivier Michielin, Ralph P. Braun, Mitchell P. Levesque, Simone M. Goldinger & Reinhard Dummer. (2017) Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research 27:4, pages 358-368.
Crossref
Crossref
Anfernee Kai-Wing Tse, Ying-Jie Chen, Xiu-Qiong Fu, Tao Su, Ting Li, Hui Guo, Pei-Li Zhu, Hiu-Yee Kwan, Brian Chi-Yan Cheng, Hui-Hui Cao, Sally Kin-Wah Lee, Wang-Fun Fong & Zhi-Ling Yu. (2017) Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biology 11, pages 562-576.
Crossref
Crossref
Min-Kyung Yeo, Min-Kyu Jung, Su-Yel Lee, Yong-Moon Lee, Gang Min Hur & Jin-Man Kim. (2017) The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. Journal of Clinical Pathology 70:3, pages 260-265.
Crossref
Crossref
Mohd Wahid, Naseem Akhter, Arshad Jawed, Sajad A. Dar, Raju K. Mandal, Mohtashim Lohani, Mohammed Y. Areeshi, Saif Khan & Shafiul Haque. (2017) Pembrolizumab’s non-cross resistance mechanism of action successfully overthrown ipilimumab. Critical Reviews in Oncology/Hematology 111, pages 1-6.
Crossref
Crossref
Paola Queirolo & Francesco Spagnolo. (2017) BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. Cancer and Metastasis Reviews 36:1, pages 35-42.
Crossref
Crossref
Jonas Cicenas, Linas Tamosaitis, Kotryna Kvederaviciute, Ricardas Tarvydas, Gintare Staniute, Karthik Kalyan, Edita Meskinyte-Kausiliene, Vaidotas Stankevicius & Mindaugas Valius. (2017) KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Medical Oncology 34:2.
Crossref
Crossref
William Bruno, Claudia Martinuzzi, Virginia Andreotti, Lorenza Pastorino, Francesco Spagnolo, Bruna Dalmasso, Francesco Cabiddu, Marina Gualco, Alberto Ballestrero, Giovanna Bianchi-Scarrà, Paola Queirolo, Federica Grillo, Luca Mastracci & Paola Ghiorzo. (2016) Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. Oncotarget 8:5, pages 8069-8082.
Crossref
Crossref
T Redmer, I Walz, B Klinger, S Khouja, Y Welte, R Schäfer & C Regenbrecht. (2017) The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis 6:1, pages e291-e291.
Crossref
Crossref
N A Doudican & S J Orlow. (2016) Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. Oncogene 36:3, pages 423-428.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
331
351
.
D. S. Mikhailenko, G. D. Efremov, N. Yu. Safronova, V. V. Strelnikov & B. Ya. Alekseev. (2017) Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. Bulletin of Experimental Biology and Medicine 162:3, pages 375-378.
Crossref
Crossref
Sara E. Patterson, Rangjiao Liu, Cara M. Statz, Daniel Durkin, Anuradha Lakshminarayana & Susan M. Mockus. (2016) The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Human Genomics 10:1.
Crossref
Crossref
Matthew L. Fisher, Gautam Adhikary, Dan Grun, David M. Kaetzel & Richard L. Eckert. (2015) The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Molecular Carcinogenesis 55:12, pages 2024-2036.
Crossref
Crossref
Seyma Demirsoy, Shaun Martin, Hannelore Maes & Patrizia Agostinis. (2016) Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma. Frontiers in Oncology 6.
Crossref
Crossref
Simona Caporali, Ester Alvino, Pedro Miguel Lacal, Lauretta Levati, Giorgio Giurato, Domenico Memoli, Elisabetta Caprini, Gian Carlo Antonini Cappellini & Stefania D’atri. (2016) Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. International Journal of Oncology 49:3, pages 1164-1174.
Crossref
Crossref
Silvana Sandri, Fernanda Faião-Flores, Manoela Tiago, Paula Comune Pennacchi, Renato Ramos Massaro, Débora Kristina Alves-Fernandes, Gustavo Noriz Berardinelli, Adriane Feijó Evangelista, Vinicius de Lima Vazquez, Rui Manuel Reis & Silvya Stuchi Maria-Engler. (2016) Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Pharmacological Research 111, pages 523-533.
Crossref
Crossref
Raveendra B. Mokhamatam, Binay K. Sahoo & Sunil K. Manna. (2016) Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death. Apoptosis 21:8, pages 928-940.
Crossref
Crossref
Hallie C. Prescott, Carolyn S. Calfee, B. Taylor Thompson, Derek C. Angus & Vincent X. Liu. (2016) Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. American Journal of Respiratory and Critical Care Medicine 194:2, pages 147-155.
Crossref
Crossref
Francesco Spagnolo, Virginia Picasso, Laura Spano, Enrica Tanda, Clary Venzano & Paola Queirolo. (2016) Update on Metastatic Uveal Melanoma: Progress and Challenges. BioDrugs 30:3, pages 161-172.
Crossref
Crossref
Anna Budina-Kolomets, Marie R. Webster, Julia I-Ju Leu, Matthew Jennis, Clemens Krepler, Anastasia Guerrini, Andrew V. Kossenkov, Wei Xu, Giorgos Karakousis, Lynn Schuchter, Ravi K. Amaravadi, Hong Wu, Xiangfan Yin, Qin Liu, Yiling Lu, Gordon B. Mills, Xiaowei Xu, Donna L. George, Ashani T. Weeraratna & Maureen E. Murphy. (2016) HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research 76:9, pages 2720-2730.
Crossref
Crossref
Max Schreuer, Geert Meersseman, Sari van Den Herrewegen, Yanina Jansen, Teofila Seremet, Ambre Bott, Ines Chevolet, Sofie Wilgenhof, Geert Maertens & Bart Neyns. (2016) Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Research 26:2, pages 157-163.
Crossref
Crossref
Erika Hamilton & Jeffrey R. Infante. (2016) Targeting CDK4/6 in patients with cancer. Cancer Treatment Reviews 45, pages 129-138.
Crossref
Crossref
Russell W Jenkins & Ryan J Sullivan. (2016)
NRAS
mutant melanoma: an overview for the clinician for melanoma management
. Melanoma Management 3:1, pages 47-59.
Crossref
Crossref
J. Tímár, L. Vizkeleti, V. Doma, T. Barbai & E. Rásó. (2016) Genetic progression of malignant melanoma. Cancer and Metastasis Reviews 35:1, pages 93-107.
Crossref
Crossref
Sebastian Zahnreich, Arnulf Mayer, Carmen Loquai, Stephan Grabbe & Heinz Schmidberger. (2016) Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future Oncology 12:1, pages 95-106.
Crossref
Crossref
Lynne T. Penberthy, Deborah M. Winn & Susan M. Scott. 2016. Oncology Informatics. Oncology Informatics
277
285
.
Jenny E Hernandez-Davies, Thai Q Tran, Michael A Reid, Kimberly R Rosales, Xazmin H Lowman, Min Pan, Gatien Moriceau, Ying Yang, Jun Wu, Roger S Lo & Mei Kong. (2015) Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. Journal of Translational Medicine 13:1.
Crossref
Crossref
Linea Melchior, Morten Grauslund, Beatriz Bellosillo, Clara Montagut, Erica Torres, Ester Moragón, Isabel Micalessi, Johan Frans, Veerle Noten, Claire Bourgain, Renske Vriesema, Robert van der Geize, Kristof Cokelaere, Nancy Vercooren, Katrien Crul, Thomas Rüdiger, Diana Buchmüller, Martin Reijans & Caroline Jans. (2015) Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Experimental and Molecular Pathology 99:3, pages 485-491.
Crossref
Crossref
Hong Li, Ganggang Li, Linxin Liu, Zhenzhen Guo, Xiaofang Ma, Ning Cao, Haihong Lin, Guang Han, Yongjian Duan & Gangjun Du. (2015) Tumor Interstitial Fluid Promotes Malignant Phenotypes of Lung Cancer Independently of Angiogenesis. Cancer Prevention Research 8:11, pages 1120-1129.
Crossref
Crossref
Richard L. Eckert, Matthew L. Fisher, Dan Grun, Gautam Adhikary, Wen Xu & Candace Kerr. (2015) Transglutaminase is a tumor cell and cancer stem cell survival factor. Molecular Carcinogenesis 54:10, pages 947-958.
Crossref
Crossref
Annalia Focà, Luca Sanguigno, Giuseppina Focà, Luigi Strizzi, Roberta Iannitti, Rosanna Palumbo, Mary Hendrix, Antonio Leonardi, Menotti Ruvo & Annamaria Sandomenico. (2015) New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding. International Journal of Molecular Sciences 16:9, pages 21342-21362.
Crossref
Crossref
Weijiang Zhang. (2015) BRAF inhibitors: the current and the future. Current Opinion in Pharmacology 23, pages 68-73.
Crossref
Crossref
Ryan SullivanPatricia LoRussoScott BoernerReinhard Dummer. (2015) Achievements and Challenges of Molecular Targeted Therapy in Melanoma. American Society of Clinical Oncology Educational Book:35, pages 177-186.
Crossref
Crossref
Victor E. ZotaAnthony M. Magliocco. (2015) Molecular Technologies in the Clinical Diagnostic Laboratory. Cancer Control 22:2, pages 142-151.
Crossref
Crossref
Joanne Monterroso, Yongli Ji, Steve Emmons & Claire Verschraegen. 2015. International Manual of Oncology Practice. International Manual of Oncology Practice
637
662
.
Chloe M. Simpson & Chris Bakal. (2018) The Dynamics of ERK Signaling in Melanoma, and the Response to BRAF or MEK Inhibition, Are Cell Cycle Dependent. SSRN Electronic Journal.
Crossref
Crossref